★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets GLP-1 Obesity Drugs Likely to Have Significant Impact on Biopharma Share Prices and Non-Healthcare Sectors The development of a new GLP-1 receptor agonist at Viking Therapeutics helped the company's shares surge by 150% this week…McAlinden Research PartnersFebruary 28, 2024
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsLabor, Education & Demographics Obesity Drug Market to Remain Heavily Concentrated Among Two Firms, Hefty US Price Tags Dominate Sales Popular GLP-1 agonists from Novo Nordisk and Eli Lilly are projected to retain a combined 80% market share among weight…McAlinden Research PartnersFebruary 20, 2024
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Billion Dollar Deals Abound as Big Pharma Continues Battle Against Patent Cliffs M&A activity among some of the largest pharmaceutical firms has gotten off to a hot start in 2024, with several…McAlinden Research PartnersJanuary 10, 2024
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Big Pharma Consolidates Its Hold on Financing for Desperate Biotech Sector, M&A to Gain Steam in 2024 Big pharma M&A activity in the new year is expected to expand, continuing a trend that gained steam throughout 2023.…McAlinden Research PartnersDecember 19, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Pfizer and Moderna Look to Put COVID Bust Behind Them, Add New Drug Development to Pipelines Several drugmakers whose sales boomed on COVID-19 vaccines and related products in 2021 and 2022 have now been embroiled in a hangover…McAlinden Research PartnersOctober 18, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareTechnology Robotic Surgical Procedures on the Rise as MedTech Firms Raise New Funds and Seek New FDA Approvals A new fundraising round by the UK's CMR Surgical, valuing the company at $3 billion, has foisted focus back onto…McAlinden Research PartnersSeptember 20, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets FTC Settles Suit Over Amgen-Horizon Deal, Potentially Averting Further Pharma M&A Hurdles The FTC's settlement with Amgen and Horizon has cleared the way for the two companies to complete a $27.8 billion…McAlinden Research PartnersSeptember 5, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareEconomics & Trade China Looks to Recharge Foreign Investment with Focus on Burgeoning Biopharma Business Some gauges indicate that foreign investment in China has sunken to 25-year lows recently. Beijing sees development of the country's biotechnology…McAlinden Research PartnersAugust 15, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsManufacturing & LogisticsMarkets Obesity Drugs’ Popularity Promises to Inject New Life Into Pharma Pipelines Summary: Ongoing shortages of popular obesity-fighting drugs from Novo Nordisk represent the surging popularity of medication-based intervention as treatment. Though…McAlinden Research PartnersJuly 25, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareMarketsPolitics & Policy Psychedelics Break New Ground in Clinical Trials, Research to be Bolstered by Key FDA Guidance New FDA guidance meant to steer clinical trials of psychedelic compounds will play a major role in the eventual approval…McAlinden Research PartnersJuly 12, 2023